Phase I combination of pazopanib and everolimus in PIK3CA mutation positive/PTEN loss patients with advanced solid tumors refractory to standard therapy.
Rodrigues HV, Ke D, Lim J, Stephen B, Bellido J, Janku F, Zinner R, Tsimberidou A, Hong D, Piha-Paul S, Fu S, Naing A, Subbiah V, Karp D, Falchook G, Kurzrock R, Wheler J.
Rodrigues HV, et al. Among authors: subbiah v.
Invest New Drugs. 2015 Jun;33(3):700-9. doi: 10.1007/s10637-015-0238-2. Epub 2015 Apr 24.
Invest New Drugs. 2015.
PMID: 25902899
Clinical Trial.